Updates are available Correction dated 2019-09-25
Click to view Correction: https://doi.org/10.1007/s10157-019-01790-x
-
Authors
Amano, Hiroaki
Ohno, Yoichi
Inoue, Tsutomu
Tomori, Koji
Ohama, Kazuya
Okada, Hirokazu
- License Information
-
More Information
Article History
Received: 4 September 2018
Accepted: 9 February 2019
First Online: 19 February 2019
Change Date: 25 September 2019
Change Type: Correction
Change Details: In the Original publication, Under the table 1, the number of participants in the April has been incorrectly published as 1373. The corrected table is given below.
Compliance with ethical standards
:
: The contributing authors reported the following financial supports: Hirokazu Okada received Astellas Pharma Inc, Takeda Pharmacological Company, Pfizer Japan Inc, MSD Inc, Novartis Pharma Japan, Otsuka Pharmacological Inc, Kyowa Hakko Kirin, Daiichi Sankyo Inc, Mitsubishi Tanabe Parma, Cyugai Pharma, Torii Pharma, Bayer Yakuhin, Boehringer-Ingelheim Japan, and Eli Lilly Japan.
: All the procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee at which the studies were conducted (IRB approval number 16–023) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: We obtained consent through the opt-out procedure from all individual participants included in the study.
